These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35326730)

  • 1. MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.
    Heugenhauser J; Galijasevic M; Mangesius S; Goebel G; Buchroithner J; Erhart F; Pichler J; Widhalm G; Stockhammer G; Iglseder S; Freyschlag CF; Oberndorfer S; Bordihn K; von Campe G; Czech T; Surböck B; Urbanic Purkart T; Marosi C; Felzmann T; Nowosielski M
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.
    Ellingson BM; Sampson J; Achrol AS; Aghi MK; Bankiewicz K; Wang C; Bexon M; Brem S; Brenner A; Chowdhary S; Floyd JR; Han S; Kesari S; Randazzo D; Vogelbaum MA; Vrionis F; Zabek M; Butowski N; Coello M; Merchant N; Merchant F
    Clin Cancer Res; 2021 Jul; 27(14):3916-3925. PubMed ID: 33863808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
    Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
    J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
    Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
    Zeyen T; Paech D; Weller J; Schäfer N; Tzaridis T; Duffy C; Nitsch L; Schneider M; Potthoff AL; Steinbach JP; Hau P; Schlegel U; Seidel C; Krex D; Grauer O; Goldbrunner R; Zeiner PS; Tabatabai G; Galldiks N; Stummer W; Hattingen E; Glas M; Radbruch A; Herrlinger U; Schaub C
    J Neurooncol; 2023 Sep; 164(3):607-616. PubMed ID: 37728779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
    de Godoy LL; Chawla S; Brem S; Wang S; O'Rourke DM; Nasrallah MP; Desai A; Loevner LA; Liau LM; Mohan S
    J Neurooncol; 2023 May; 163(1):173-183. PubMed ID: 37129737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparative Retrospective Study of Immunotherapy RANO
    Chen X; Lim-Fat MJ; Qin L; Li A; Bryant A; Bay CP; Gao L; Miskin N; Liu Z; Iorgulescu JB; Xu X; Reardon DA; Young GS
    Front Oncol; 2021; 11():679331. PubMed ID: 34249718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria.
    Roh YH; Park JE; Kang S; Yoon S; Kim SW; Kim HS
    Cancer Imaging; 2023 Oct; 23(1):102. PubMed ID: 37875970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
    Wen PY; van den Bent M; Youssef G; Cloughesy TF; Ellingson BM; Weller M; Galanis E; Barboriak DP; de Groot J; Gilbert MR; Huang R; Lassman AB; Mehta M; Molinaro AM; Preusser M; Rahman R; Shankar LK; Stupp R; Villanueva-Meyer JE; Wick W; Macdonald DR; Reardon DA; Vogelbaum MA; Chang SM
    J Clin Oncol; 2023 Nov; 41(33):5187-5199. PubMed ID: 37774317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.
    Buchroithner J; Erhart F; Pichler J; Widhalm G; Preusser M; Stockhammer G; Nowosielski M; Iglseder S; Freyschlag CF; Oberndorfer S; Bordihn K; von Campe G; Hoffermann M; Ruckser R; Rössler K; Spiegl-Kreinecker S; Fischer MB; Czech T; Visus C; Krumpl G; Felzmann T; Marosi C
    Cancers (Basel); 2018 Oct; 10(10):. PubMed ID: 30301187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
    Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
    Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma.
    Hoff BA; Lemasson B; Chenevert TL; Luker GD; Tsien CI; Amouzandeh G; Johnson TD; Ross BD
    Acad Radiol; 2021 Dec; 28(12):1711-1720. PubMed ID: 32928633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults.
    Ellingson BM; Sanvito F; Cloughesy TF; Huang RY; Villanueva-Meyer JE; Pope WB; Barboriak DP; Shankar LK; Smits M; Kaufmann TJ; Boxerman JL; Weller M; Galanis E; Groot J; Gilbert MR; Lassman AB; Shiroishi MS; Nabavizadeh A; Mehta M; Stupp R; Wick W; Reardon DA; Vogelbaum MA; van den Bent M; Chang SM; Wen PY
    AJNR Am J Neuroradiol; 2024 Jun; ():. PubMed ID: 38926092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.
    Han K; Ren M; Wick W; Abrey L; Das A; Jin J; Reardon DA
    Neuro Oncol; 2014 May; 16(5):696-706. PubMed ID: 24335699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of pseudoprogression in patients with glioblastoma.
    Kucharczyk MJ; Parpia S; Whitton A; Greenspoon JN
    Neurooncol Pract; 2017 Jun; 4(2):120-134. PubMed ID: 31386017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
    J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
    Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation.
    Linhares P; Carvalho B; Figueiredo R; Reis RM; Vaz R
    J Oncol; 2013; 2013():690585. PubMed ID: 24000284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?
    Olivier T; Migliorini D
    Rev Neurol (Paris); 2023 Jun; 179(5):502-505. PubMed ID: 37012085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.